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Surfactant administration in 
premature infants with RDS 
ABSTRACT
Background. The significant advancement in the treatment of respiratory distress syndrome can be attributed to prenatal 
identification of high risk pregnancies, prevention of illness through antenatal care, prenatal administration of glucocorti-
coids, advancement in respiratory support and surfactant therapy. These measures resulted in the reduction of mortality 
and morbidity rates in preterm infants.
Patients and methods. We analyzed data of 78 preterm babies with respiratory distress syndrome hospitalized in the NICU 
of the Pediatric Clinic, KCU Sarajevo. All children included in the study were mechanically ventilated and treated with one or 
more doses of bovine surfactant (Survanta) as rescue therapy. Surfactant was given to children with clinical and radiological 
signs of RDS, who required FiO2>0,40. We used the standard procedure of giving surfactant therapy to intubated children 
in sterile conditions, after we confirmed, by X-ray, correct tube placement.
Results. We investigated the clinical efficacy of surfactant in relation to time of administration, O2 requirement and necessity 
of one or more doses of surfactant. We found that early treatment with surfactant replacement- within 6 hours of birth- is more 
effective, and resulted in  a significant reduction of mortality rate (p<0,01). Treatment with multiple doses is more effective 
in comparison to one dose, although there was not a significant difference (p<0,20) between the treated groups. There is a 
significant difference (p<0,01) between groups related to O2 requirement. In the group of babies which required 60% or more 
O2 concentration in inhaled air at the time of surfactant replacement, mortality rate was significantly higher (p<0,01).
Conclusion. Our study confirmed the benefits of surfactant therapy in preterm babies with respiratory distress syndrome. We 
confirmed the advantages of early treatment vs. late treatment, but we could not confirm the obvious advantage of multiple 
over single doses. So, a reasonable recommendation is to treat the infants as soon as clinical signs of developing respira-
tory distress appear with an individual dose for each infant.
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Introduction
Respiratory distress syndrome, (RDS, 
hyaline membrane disease, hyposur-
factosis) is the most common distur-
bance in preterm infants, appearing 
in approximately 60% of infants born 
before 30 weeks gestation. The main 
cause of the disease is inadequate 
amounts of lung surfactant.  Surfactant 
replacement reduces mortality and 
morbidity rates in premature infants, 
reduces duration of ventilatory support, 
number of complications and medical 
costs. Surfactant therapy is not a sub-
stitute for an attempt to increase lung 
maturity by delaying premature delivery 
or by using antenatal corticosteroids 
with the aim of preventing RDS (1-5).
Many studies of different regimes of 
surfactant therapy, related to time of 
application, have been undertaken dur-
ing the 80s and 90s (6,7,8).
Prophylactic surfactant replacement is 
given to preterm neonates at high risk 
of developing acute RDS in the delivery 
room, shortly after resuscitation, as they 
start to breathe. Rescue therapy refers 
to treatment given after the diagno-
sis is established, 2 to 24 hours after 
birth (3,9-11). Most centers use res-
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cue therapy as the mode of treatment. 
Each regime increases oxygenation of 
ventilated preterm babies and reduces 
mortality and morbidity rates. This cor-
relates with a significant reduction of 
medical costs (12,13,14). 
The aim of this study was to find an 
optimal regime of surfactant therapy, 
early vs. late treatment, and also to 
test the efficacy of multiple doses vs. a 
single dose.
Patients and methods
The investigation included 78 preterm 
infants with RDS, between 25 and 
35 weeks gestation, treated with sur-
factant. All children were hospitalized in 
the neonatal intensiv care unit (NICU) 
of the Pediatric Clinic, Clinical Centre 
Sarajevo during 2004 and 2005.
Surfactant was given to infants with 
radiological and clinical signs of RDS 
(tachypnea, cyanosis on room air) who 
required more then 40% O2 in inhaled 
air. Surfactant was given after intuba-
tion, radiological confirmation of correct 
tube placement and stabilization of vital 
functions. We used bovine surfactant 
- Survanta, 4ml/kg, which was adminis-
tered according to standard procedures. 
The following parameters were chosen 
on the ventilator: PIP (Positive Inspiratory 
Pressure) needed for the rising of the 
chest but without overdistension; pres-
sure at the end of expiration (PEEP) of 4 
cm H2O; inspiratory time (IT) of 0,5 sec., 
frequency of 30/min, start FiO2 1,0. Sur-
factant was given in one or more doses, 
in sterile conditions. The second dose 
was given 12 hours after the first dose. 
Each dose was administered over 30s 
into each lung quadrant. If saturation fell 
below 85% we stopped with the instil-
lation. Treatment was continued after 
O2 saturation improved upon previous 
values. Effects of surfactant therapy were 
assessed based on O2 saturation (deter-
minated by pulse oximetry), gas analyses 
in arterial and capillary blood, the clinical 
condition of the child and chest X-ray.
The group of investigated children was 
divided into subgroups, depending on 
the number of doses received, time of 
treatment (early, late) and O2 require-
ment. Early treatment was related to 
patients who received the first dose 
within 6 hours of birth and late treatment 
- six or more hours after birth. In regard 
to O2 requirements, our study group 
was divided into those who needed < 
60%O2 in inhaled air and those who 
needed 60% O2 or more.
Results
Comparing the results of early treat-
ment (giving Surfactant within 6 hours 
of birth) and late treatment (six or more 
hours after birth) we found that there is 
a significant difference between treated 
groups (p=0,005). In the study group 
which received surfactant within 6 hours 
of birth, 34 (out of 43) children survived, 
compared with 17 (out of 35) children 
who received surfactant 6 hours after 
birth or later (table 1).
Table1. 
Outcome of illness in relation to time of first surfactant dose
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Outcome of illness in relation to number of doses
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From the table 2, it can be seen that 
53 (out of 78) children received one 
dose of surfactant comparable with 
25 who received two doses. 38 (out of 
53) children, who received one dose 
survived, whereas, only 13 (out of 25) 
children who received two doses sur-
vived. There is no significant difference 
between these two groups (p=0,088), 
although the mortality rate in children 
who received two doses of surfactant 
was lower in comparison with the group 
which received one dose. 
There is a significant difference (p= 
0,015) between groups related to O2 
requirement. In the group of children 
requiring O2 concentration less then 
60% (n=22), as many as 19 (out of 22) 
survived in comparison with the group 
who required 60% or more oxygen, 
at the time of surfactant replacement, 
where 32 (out of 56) children survived 
(table 3). Early treatment with surfactant 
at lower O2 concentrations is associ-
ated with a lower mortality rate.
Discussion
Many clinical trials, carried out dur-
ing the 80s and 90s, showed that sur-
factant use in preterm infants signifi-
cantly reduces mortality rate and com-
plications within 28 days of birth (9,12). 
Our study, conducted on 78 preterm 
babies, showed that the overall per-
centage of survival in children treated 
with surfactant was 65,38%.
Generally, surfactant is being given 6-
24 hours after birth, as rescue therapy, 
when diagnosis of severe respiratory 
distress syndrome is established. On 
the other hand, treatment in the delivery 
room is considered optimal, only if it’s 
given after establishing breathing and 
ventilation by positive pressure. In most 
of the studies, treatment of RDS with sur-
factant started between 2-4 hours after 
birth or in the delivery room after stabili-
zation of the baby, within 15 minutes of 
birth. In relation to timing of the first dose, 
two strategies are used (7,15,16).
In our study, the first dose of surfactant 
was given as soon as diagnosis of 
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Table 3. 
Outcome of illness dependent upon O2 requirement
  Hours
  <0,6






















severe respiratory distress syndrome 
was established: within 6 hours from 
birth (early treatment) and after 6 hours 
(late treatment). In the study group 
which received surfactant within 6 
hours of birth, 34 (out of 43) children 
survived, compared with 17 (out of 
35) children who received surfactant 
6 hours after birth or later (p<0,005). 
Our results confirm the advantages of 
early treatment vs. late treatment. So, a 
reasonable recommendation is to treat 
the infants as soon as clinical signs of 
developing respiratory distress appear. 
Waiting for the complete clinical pic-
ture to develop before commencing 
treatment will minimize the effect of 
surfactant therapy (17,18). The treat-
ment in the delivery room should be 
reserved for the smallest infants with 
the highest risk for developing acute 
RDS and should be given by a person 
experienced in neonatal resuscitation 
and surfactant administration (19).
In most cases, multiple doses of sur-
factant are being given, with the intent 
of avoiding functional inactivation of sur-
factant. Multiple doses are believed to be 
useful because the effect of one dose is 
considered transient (10,20). When com-
paring multiple doses with single doses, 
authors (7, 9,21) have found a reduction 
in the frequency of pneumothorax and 
mortality rate (within 28 days) with multi-
ple doses. It is not clear whether all sick 
infants benefit from multiple doses. Most 
children respond to treatment or re-treat-
ment, but some of them show little or no 
response. These infants can have other 
illnesses like pneumonia, pulmonary 
hypoplasia or congenital heart disease. 
Structural immaturity of the lungs and 
birth asphyxia can reduce the response 
to surfactant therapy (23,22).
In our study, there was no significant 
difference between groups treated with 
one and two or more doses (p<0,088), 
although the mortality rate in children 
who received two doses of surfactant 
was lower compared with the group 
which received one dose. The neces-
sity for more doses should be individu-
alized and considered based on clinical 
circumstances, such as in infants with 
residual lung disease, so that the risk 
of complications like pneumothorax or 
prolonged ventilatory support can be 
avoided (24,25).
It seems that early surfactant treatment, 
when O2 requirement is lower, reduces 
the need for later treatment, O2 require-
ment and mechanical ventilation. Sur-
factant given early is more effective. 
The optimal time for administration is 
not defined. The current recommenda-
tion is that a preterm baby with RDS 
needs surfactant replacement if he/she 
needs endotracheal intubation and if 
O2 requirement in inhaled air is more 
than 40% (26,27). In our study there is a 
significant difference (p<0,05) between 
groups related to O2 requirement. In 
the group of children which required O2 
concentrations less than 60% (n=22), 
as many as 19 (out of 22) survived com-
pared with 32 (out of 56) who required 
60% or more oxygen concentration 
in inhaled air at the time of surfactant 
replacement. Early treatment of sur-
factant with lower O2 requirements is 
associated with a lower mortality rate.
Our study confirmed the benefits of sur-
factant use in preterm babies with respi-
ratory distress syndrome. We confirmed 
the advantages of early treatment vs. late 
treatment, which is also connected with 
O2 requirement. In this study we could 
not confirm the advantage of multiple 
over single doses. Therefore a reason-
able recommendation is to treat infants 
as soon as clinical signs of developing 
respiratory distress appear with individu-
alized dosaging for each infant.
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